via University of Waterloo
Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.
The vaccine will work by using bacteriophage, a process that will allow the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.
“When complete, our DNA-based vaccine will be administered non-invasively as a nasal spray that delivers nanomedicine engineered to immunize and decrease COVID-19 infections,” explains Roderick Slavcev, a professor in the School of Pharmacy who specializes in designing vaccines, pharmaceuticals and gene-therapy treatments. “This research combines the expertise of many and leverages existing technology developed by my team, which we’re reconfiguring for a COVID-19 application.”
When completed, the researchers aim to have the DNA-based vaccine enter cells in targeted tissues and cause them to produce a virus-like particle (VLP) that will stimulate an immune response in people.
The VLP will look similar to the structure of SARS-CoV-2 (the virus which causes COVID-19), but is harmless. This similarity will activate the body’s natural immune response to protect against viral infections comparable to the VLP, including SARS-CoV-2. It will also bind to receptors that SARS-CoV-2 would bind to, limiting the possible sites for transmission. By causing these changes in the body, the vaccine will build immunity against COVID-19 and decrease the severity of infections in progress – serving as both a therapeutic and a vaccine.
Every detail of the vaccine, from ensuring the bacteriophage target specific cells in the respiratory tract to creating a minimal VLP to impersonate SARS-CoV-2, is specifically engineered by the researchers and requires testing.
To achieve the design of such a complex project, Slavcev is teaming up with Emmanuel Ho, another professor at the School of Pharmacy, and Marc Aucoin, professor of chemical engineering. Ho’s team is designing the nanomedication that will be delivered by the nasal spray, which is currently being tested. Aucoin’s lab is constructing and purifying the VLP and boosting immunity following the initial administration of the therapeutic vaccine.
“It is the collaborative effort of our talented teams that makes this multidisciplinary project so feasible and necessarily efficient as a potential universal vaccine solution against SARS-CoV infections,” says Slavcev. “To practice science with such urgency alongside such talented colleagues and their students is not only immensely educational, it is extremely rewarding.”
Slavcev’s team has completed design of the bacteriophage delivery system and is currently modifying this system to apply to COVID-19. Additional design of components and further testing will take place later this year. Components of the research are supported by a grant from the Natural Sciences and Engineering Research Council of Canada.
Note: This research has not yet been peer-reviewed and is being released as part of UWaterloo’s commitment to help inform Canada’s COVID-19 response.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
DNA-based COVID-19 vaccine
- Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model
In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory ...
- COVID-19 has worsened health inequities for communities of color, report shows
Disproportionate impacts amongst communities of color highlight the need for an equity focused COVID-19 response.
- Want the new COVID-19 vaccine booster? No problem, unless it’s got to be Moderna
If you want the new COVID-19 booster that protects against the latest circulating omicron variants, you have lots of options for appointments, except if you have your heart set on Moderna. People ...
- Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts
Advocates for patients and doctors say the FDA "user fee" program has enabled the industry to weaken the approval process meant to ensure drugs are safe and effective ...
- WHO 'strongly advises against' use of two COVID-19 antibody therapies: BMJ
The WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19.
Go deeper with Google Headlines on:
DNA-based COVID-19 vaccine
Go deeper with Bing News on:
- No COVID-19 vaccine doses administered in Azerbaijan over past 24 hours
No one was vaccinated against COVID-19 in Azerbaijan over the past 24 hours, Trend reports referring to the Operational Headquarters under the Azerbaijani Cabinet of Ministers. Totally, up until now, ...
- Interest in COVID-19 vaccines for kids remains low
Interest in COVID-19 vaccines for young children has remained low since regulators approved shots for those ages 6 months to 4 years old over the summer.
- COVID questions: Are the new vaccine boosters still free? Who’s eligible?
For most Michiganders who are vaccinated against COVID-19, it’s likely been a while since you’ve had to think about securing a shot. But health officials recently began recommending a new, bivalent ...
- 5 reports of 'serious adverse events' in over 18,000 doses of Nuvaxovid Covid-19 vaccine administered: HSA
More than 18,000 doses of Nuvaxovid vaccine have been administered as of Aug 31, with 28 reports of adverse reactions, of which 82 per cent — or 23 cases — were not serious, said the Health Sciences ...
- More than 18,000 doses of Nuvaxovid COVID-19 vaccine administered, 5 cases of severe reactions recorded
SINGAPORE: More than 18,000 doses of Novavax’s Nuvaxovid COVID-19 vaccine have been administered as of Aug 31, with five cases of severe side effects reported. In its 13th vaccine safety report on ...